Pure Global

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer - Trial NCT06389006

Access comprehensive clinical trial information for NCT06389006 through Pure Global AI's free database. This Phase 2 trial is sponsored by RemeGen Co., Ltd. and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 79 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06389006
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06389006
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
A Single-arm, Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Study Focus

Breast Cancer

Disitamab Vedotin for Injection

Interventional

drug

Sponsor & Location

RemeGen Co., Ltd.

Shanghai, China

Timeline & Enrollment

Phase 2

Apr 30, 2024

Dec 31, 2026

79 participants

Primary Outcome

Total pathological complete response (tpCR) rate

Summary

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin
 combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low
 breast cancer

ICD-10 Classifications

Malignant neoplasm of breast
Malignant neoplasm of breast
Carcinoma in situ of breast, unspecified
Malignant neoplasm: Breast, unspecified
Other carcinoma in situ of breast

Data Source

ClinicalTrials.gov

NCT06389006

Non-Device Trial